Target Discovery - From Omics to Knowmics

Home » About TDI » Business Development » Licensing

Main Menu

Home
About TDI
   Management Team
   Business Development
      Collaborations
      Client-Funded Work
      Licensing
      Current Partners
   Intellectual Property
Isonostic™ Products
Corporate Communications
Careers
Contact Us
Site Map

PDF Viewer

Adobe Reader 6.0 or higher is required to view our PDF documents.

Licensing

In-Licensing

TDI intends to in-license existing intellectual property relating to cancer isoform biomarkers, to complement our internal discovery efforts. We will actively seek to license protein biomarkers known or suspected to have isoform differences relevant to our disease areas of interest.

Out-Licensing

TDI has a diverse portfolio of intellectual property pertaining to the discovery and validation of protein targets and biomarkers, for which we are actively interested in developing out-licensing relationships. We can provide out-license access to our patented mass defect technology, to explore, identify and validate clinical protein isoform biomarkers. Partners may gain access to several other proprietary TDI technologies as well (see Intellectual Property - Other).

If you are interested in out-licensing validated protein biomarkers that have proven isoform differentiation, or you would like to discuss licensing of TDI technologies, please contact:

bizdev@targetdiscovery.com
Toll Free: (877) 834-4620